Description
Prashanthan Sanders, MBBS, PhD, FHRS of the University of Adelaide as he discusses Magnetic resonance imaging based Dual lead cardiac Resynchronization therapy: A prospective Left Bundle Branch Pacing Study (MADURAI LBBP study) by Heart Rhythm 2023 Late-Breaking Abstract Author Shunmuga Sundaram Ponnusamy. He is joined by guests Rakesh Gopinathannair, MA, MD, FHRS of the Kansas City Heart Rhythm Institute and Martin K. Stiles, MBChB, PhD, FHRS of Waikato Hospital, Cardiology. This episode of The Lead was recorded in front of live audience at Heart Rhythm 2023 in New Orleans, Lousiana.
Learning Objectives
- Analyze the left bundle branch pacing study.
Article Authors and Podcast Contributors
Article Authors
Shunmuga Sundaram Ponnusamy, MBBS, MD, CEPS-A; Vidhya Ganesan, MD; Vadivelu Ramalingam, MD; Thabish Syed, MD; Selvaganesh Mariappan, MD; Senthil Murugan, MD; Mahesh Kumar, MD; Vijesh Anand, MD; Mariappan Murugan, MD; Pugazhendhi Vijayaraman, MD, FHRS
Podcast Contributors
Rakesh Gopinathannair, MA, MD, FHRS of the Kansas City Heart Rhythm Institute
Prashanthan Sanders, MBBS, PhD, FHRS of the University of Adelaide
Martin K. Stiles, MBChB, PhD, FHRS of Waikato Hospital, Cardiology
Disclosure Policy
ACE Disclosure Policy
The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.
Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.
ACCME Definition:
*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
All relevant financial relationships have been mitigated.Host Disclosure(s):
P. Sanders: Honraria/Speaking/Consulting Fee: Abbott, Boston Scientific, Medtronic; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Becton Dickinson, Boston Scientific, CathRx, EBR Systems, Medtronic, Microport Scientific Corporation, PaceMate
Contributor Disclosure(s):
R. Gopinathannair: Honoraria/Speaking/Consulting Fee: Abbott, Boston Scientific, Biosense Webster
M. Stiles: Honoraria/Speaking/Consulting Fee: Medtronic, Cyrix Medical, Pfizer, Sanofi
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.